Wilcox RAPTAR Xe

Archive for November, 2015

London Bridge Trading – Black Friday 2016

Tuesday, November 24th, 2015

LBT-BF_01

LBT is holding a Black Friday and Cyber Monday sale. Staring November 26th at noon EST and running through November 30th at Midnight EST, take advantage of discounts on LBT gear, and get $25 off orders of $300 or more.

lbtinc.com

Spuhr AB Makes Mount For FBI HRT T-2s

Tuesday, November 24th, 2015

  

This is the mount selected by the FBI’s Hostage Rescue Team for use with the Aimpoint T-2 optic. The mount comes in four different heights, 22mm, 30mm, 39mm and 42mm.  Additionally, it incorporates the Spuhr interfaces on one side, so the user can hang a laser or something else, directly on to the mount.

 

spuhrwebshop.com/en/aimpoint

Magpul Now Shipping CORE Gloves

Tuesday, November 24th, 2015

Untitled

Magpul is now shipping all five four of the models of CORE gloves announced last week: CORE Flight Glove, CORE Breach Glove (FR and non-FR), CORE Technical Glove, and CORE Patrol Glove. The CORE Ranch Glove is slated for an early 2016 release.

CORE Gloves

www.magpul.com/gloves

UPDATED – US Government Sues L3 Communications for Fraud Involving EOTech Sights – L3 Settles for $25.6 Million

Tuesday, November 24th, 2015

We can finally tell you the rest of the story regarding L3 Communications’ EOTech Sights.  The Department of Justice has been investigating EOTech for some time and has finally filed suit (US v. L-3 Communications EOTech Inc., 15-cv-09262) in US District Court, Southern District of New York (Manhattan).

Specifically, the Government’s allegations concentrate on the performance of the Holographic Weapon Sights at temperature extremes as well as in high moisture environments. The Government also claims that EOTEch failed to disclose testing that demonstrated the inaccuracy issues in those environments.

In addition to naming L-3 and EOTech as defendants in the Government’s suit, they also named EOTech’s president, Paul Mangano which isn’t very common. They are seeking unspecified triple damages plus civil penalties of as much as $11,000 for each fraudulent claim.

L-3 has been aware of the pending action, having mentioned the issue in their July 2015 SEC filing as well as setting aside $26 million.

Update – By mid-afternoon, L-3 had settled with the government for $25.6 million which clearly indicates L-3 has known since summer how much the US Government would be willing to accept in relief. Their quick action helped turn a drop in stock value of more than 6% at mid-day, yet they still closed the day down from opening prices.

What remains, is for L-3 to answer to domestic consumers, state and local governments as well as international customers.

Below is the filing. In suggest you read it. The Government’s case is compelling.

United States v. L-3 Communications Eotech, Inc., et al-1

Click to view .pdf

GSS Gear – Black Friday

Tuesday, November 24th, 2015

These deals are for their Va Beach location.  
Shoppers enjoy a catered lunch at by 11:30.

  
www.gssgear.com

Project Diane

Tuesday, November 24th, 2015

Project Diane is a United States Army Special Operations Command initiative which looks at ways to expand women’s roles within the command. It takes its name from Office of Strategic Services member Virginia Hall, codename ‘Diane.’

FBI HRT Adopts Aimpoint T-2

Tuesday, November 24th, 2015

The FBI’s Hostage Rescue Team and Defensive Systems Unit are now being issued the Aimpoint Micro T-2 and Micro H-2, respectively. This seems to be a direct result of the recent fallout regarding the issues with EOTech optics.

T-2

Federal Burearu of Investigation Selects Aimpoint Micro Sights for use by elite teams

Chantilly, VA – November 24, 2015 – Aimpoint, the originator and worldwide leader in electronic red-dot sighting technology, has announced that the US Federal Bureau of Investigation (FBI) is now issuing Aimpoing Micro Series Sights to agents in the Hostage Rescue Team (HRT) and Defensive Systems Unit (DSU).

The FBI conducted rigorous testing on optics from a wide variety of manufacturers. Following this selection process, the Aimpoint Micro T-2 and Micro H-2 were authorized as issued optics. The Micro T-2 was chosen for use by the HRT, and the Micro H-2 was selected by the DSU.

Contracts were awarded via competitive bidding process, and Aimpoint Dealers began shipments to the FBI in July, 2015.

For more information on Aimpoint or the Aimpoint Micro T-2 or Micro H-2, visit the company’s webpage at: www.aimpoint.com.

B-TEMIA Initiates Pivotal Clinical Trial To Support Commercial Launch Of Keeogo In The U.S.

Tuesday, November 24th, 2015

– Partnering with three of the most reputable rehab centers in North America –

Quebec, November 23, 2015 – B-TEMIA Inc., the market leader in human augmentation, today announced that it has initiated a multi-centre pivotal clinical trial, aimed at demonstrating the superior clinical benefits and safety for home use of its powered assistive DemoskeletonTM technology, called Keeogo, for patients suffering from reduced mobility due to their medical conditions. Led by Principal Investigator, Dr. Chris A. McGibbon, PhD, from the University of New Brunswick’s, Faculty of Kinesiology and Institute of Biomedical Engineering, the study is expected to generate the required data to support the submission of a 510(k) pre-market notification to the U.S. Food and Drug Administration in 2016, a prerequisite to start commercialization in the United States.

“This is the first international clinical trial involving the DermoskeletonTM technology that aims at demonstrating the efficacy and safety of Keeogo™ during everyday community and home mobility use, something that has not been possible in the past with other exoskeleton technologies that were developed principally for use in a clinical rehabilitation setting,” stated Dr. Chris A. McGibbon.

As part of the trial, B-TEMIA has partnered with three of the most reputable rehabilitation institutions in North America: the Rehabilitation Institute of Chicago, the Spaulding Rehabilitation Hospital Boston, and the Toronto Rehabilitation Institute–UHN.

“This pivotal clinical trial will be key in supporting the commercial launch of KeeogoTM in the U.S. market. Based on earlier very positive pilot studies, we are confident that it will demonstrate how Keeogo™ could significantly improve the daily activities of those who suffer from disabilities that impact their mobility,” said Mr. Stéphane Bédard, President & CEO of B-TEMIA.

www.b-temia.com

www.keeogo.com